Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia.
- Author:
Jun LUO
1
;
Zhi-Gang PENG
;
Yan CHEN
;
Yong-Rong LAI
;
Yu-Ying LU
;
Shan-Jun SONG
Author Information
1. Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Benzamides;
Bone Marrow Cells;
metabolism;
DNA-Activated Protein Kinase;
biosynthesis;
genetics;
Female;
Fusion Proteins, bcr-abl;
biosynthesis;
genetics;
Humans;
Imatinib Mesylate;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
genetics;
therapy;
Male;
Middle Aged;
Peripheral Blood Stem Cell Transplantation;
Piperazines;
therapeutic use;
Pyrimidines;
therapeutic use;
RNA, Messenger;
biosynthesis;
genetics
- From:
Journal of Experimental Hematology
2007;15(2):248-252
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the expression and regulation mechanism of DNA-dependent protein kinase catalylic subunit (DNA-PKcs) in chronic myeloid leukemia (CML) and its role in blast crisis of CML. Expression of DNA-PKcs mRNA was detected by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and DNA-PKcs protein by Western blot in 62 CML patients and K562, as compared to those of 23 normal individual controls. In 26 CML patients received allogeneic peripheral blood stem cell transplantation (allo-PBSCT) and 4 CML patients treated with imatinib, the expression of bcr-abl mRNA and DNA-PKcs protein was detected by RT-PCR and Western blot, respectively. After treatment with imatinib in mononuclear cell (MNC) of CML patients and K562 in vitro, expression of DNA-PKcs mRNA was detected by RT-PCR and DNA-PKcs protein level, tyrosine phosphorylation of bcr-abl fusion protein were detected by Western blot. The results showed that the expression of DNA-PKcs protein was significantly lower in CML and K562 than those in normal control (P<0.05). In 26 CML patients received allo-PBSCT and 4 CML patients treated with imatinib, the expression of DNA-PKcs protein was enhanced while the expression of bcr-abl mRNA decreased. After treatment of MNC of CML and K562 with imatinib in vitro, the expression of DNA-PKcs protein was enhanced while tyrosine phosphorylation of bcr-abl fusion protein decreased. It is concluded that the expression of DNA-PKcs protein is down-regulate by bcr-abl fusion gene, and the bcr-abl fusion gene down-regulate the expression of DNA-PKcs protein by post-transcriptional mechanism; the decrease of DNA-PKcs protein expression may be one of mechanisms underlying the acute transformation of CML.
